Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
4.050
-0.100 (-2.41%)
At close: Dec 20, 2024, 4:00 PM
4.200
+0.150 (3.70%)
After-hours: Dec 20, 2024, 6:32 PM EST
Trevi Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Trevi Therapeutics stock have an average target of 9.31, with a low estimate of 6.00 and a high estimate of 21. The average target predicts an increase of 129.88% from the current stock price of 4.05.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TRVI stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 4 | 5 | 5 | 5 |
| Buy | 1 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 6 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +418.52% | Dec 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 → $7.5 | Strong Buy | Reiterates | $6 → $7.5 | +85.19% | Dec 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $7.5 | Strong Buy | Maintains | $6 → $7.5 | +85.19% | Dec 12, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +418.52% | Dec 12, 2024 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +97.53% | Dec 12, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.50
from -0.29
EPS Next Year
-0.50
from -0.50
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 6.2M | |||
| Avg | n/a | n/a | 668,671 | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.49 | -0.42 | -0.26 | |||
| Avg | -0.50 | -0.50 | -0.53 | |||
| Low | -0.51 | -0.57 | -0.71 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.